Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Larger Is The Graft Versus Host Disease (GVHD) Treatment Market Expected To Become By 2029 Compared With Its 2025 Level?
The graft versus host disease (gvhd) treatment market size has experienced robust growth in recent years. It is anticipated to expand from $2.85 billion in 2024 to $3.06 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.4%. This historical expansion can be attributed to an increase in the number of allogeneic transplantations, the growing incidence of acute GVHD, an increasing rate of hematopoietic stem cell treatment, rising demand for bone marrow transplants, the rising prevalence of GVHD worldwide, an increase in chronic GVHD cases, advancements in technology, and a rise in the patient population.
The graft versus host disease (gvhd) treatment market size is projected for substantial expansion over the upcoming years. Its valuation is anticipated to reach $4 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.9%. This growth trajectory throughout the forecast period stems from factors such as an Increase in the number of allogeneic transplantations, the growing incidence of acute GVHD, an increasing the rate of hematopoietic stem cell treatment, the rising demand for bone marrow transplants, the rising prevalence of GVHD worldwide, an increase in chronic GVHD cases, advancements in technology, and a rise in the patient population. Key developments shaping the market during this period encompass partnerships, investment, product approvals, and customizations.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15579&type=smp
What Are The Main Drivers Boosting The Graft Versus Host Disease (GVHD) Treatment Industry’s Expansion?
An increase in hematological disorders is projected to boost the growth of the graft versus host disease (GVHD) treatment market in the future. Also referred to as blood disorders, hematological disorders include various conditions impacting blood and its elements like red blood cells, white blood cells, platelets, and plasma. These disorders are becoming more prevalent because of factors such as poor lifestyle choices, genetic susceptibility, and exposure to environmental toxins like radiation, chemicals, and pollutants. Treatment approaches designed for GVHD management could have wider benefits for individuals suffering from hematological disorders, providing new ways to regulate the immune system and enhance disease control. For example, data from the US-based Leukemia & Lymphoma Society indicates that in 2023, approximately 57,380 people in the US are anticipated to die from leukemia, lymphoma, and myeloma. This figure translates to around 157 daily deaths or over six hourly deaths in the US due to blood cancer. Consequently, the increasing incidence of hematological disorders is a key driver for the graft versus host disease (GVHD) treatment market.
What Are The Segment Types Shaping The Graft Versus Host Disease (GVHD) Treatment Market?
The graft versus host disease (gvhd) treatmentmarket covered in this report is segmented –
1) By Product Type: Corticosteroids; Monoclonal Antibodies; Immunosuppressants; Others
2) By Disease Type: Acute GvHD; Prophylaxis GvHD; Chronic GvHD
3) By End User: Hospitals Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Corticosteroids: Prednisolone; Methylprednisolone; Dexamethasone; Hydrocortisone; Betamethasone; Budesonide
2) By Monoclonal Antibodies: Anti-Inf Monoclonal Antibodies ( Infliximab, Adalimumab); Anti-il-2ra Monoclonal Antibodies ( Basiliximab); Anti-cd52 Monoclonal Antibodies (Alemtuzumab); Anti-il-6 Monoclonal Antibodies (Tocilizumab); Anti-Cd20 Monoclonal Antibodies (Rituximab)
3) By Immunosuppressants: Calcineurin Inhibitors (Cyclosporine, Tacrolimus); Methotrexate; Mycophenolate Mofetil; Azathioprine; Sirolimus (Rapamycin); Cyclophosphamide
4) By Others: Mesenchymal Stem Cells (Mscs); Jak Inhibitors ( Ruxolitinib); Extracorporeal Photopheresis (Ecp); Thalidomide; Antithymocyte Globulin (Atg); Colony-Stimulating Factors (Filgrastim)
How Are Trends Influencing The Graft Versus Host Disease (GVHD) Treatment Market?
Companies operating in the graft versus host disease (GVHD) treatment market are actively developing advanced drugs and seeking their approval for the treatment of graft versus host disease (GVHD) to gain a competitive advantage. Obtaining product approvals is crucial for ensuring that healthcare products comply with the necessary standards for safety, efficacy, and quality before they become available to patients. For instance, in March 2023, Incyte corporation, a US-based healthcare company, developed ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, which was approved by the Food and Drug Administration, a US-based healthcare organization. These tablets were designed for once-daily use in treating specific types of myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).
Who Are The Prominent Global Companies Shaping The Graft Versus Host Disease (GVHD) Treatment Market?
Major companies operating in the graft versus host disease (GVHD) treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol Myers Squibb, AstraZeneca, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly And Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Biogen Inc., Astellas Pharma Inc., Jazz Pharmaceuticals plc, Allergan plc, Incyte Corporation, Mallinckrodt Pharmaceuticals, Genzyme Corporation, Kiadis Pharma, Neovii Pharmaceuticals AG, ElsaLys Biotech SA, Mesoblast Ltd., Soligenix
Download The Full Report For Exclusive Market Findings:
Which Geographies Are Emerging As Strong Markets For The Graft Versus Host Disease (GVHD) Treatment Industry?
North America was the largest region in the graft versus host disease (GVHD) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the graft versus host disease (GVHD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Graft Versus Host Disease (GVHD) Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=15579&type=smp
Browse Through More Reports Similar to the Global Graft Versus Host Disease (GVHD) Treatment Market 2025, By The Business Research Company
Vascular Grafts Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/vascular-grafts-global-market-report
Bone Grafts And Substitutes Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/bone-grafts-and-substitutes-global-market-report
Coronary Artery Bypass Graft Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/coronary-artery-bypass-graft-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model